Which way now? Solutions to find your way through three difficult challenges in Molecular Dx consumables development.
Developing and manufacturing microfluidic consumables for molecular diagnostics is complex. This presentation will discuss solutions to defeat three key challenges a company will face when developing such a consumable product.
Development and Manufacture of Point of Care and Lifescience Devices
SCHOTT MINIFAB an ISO 13485 / ISO 9001 certified developer and manufacturer of point-of-care devices and research consumables for diagnostics, lifescience and other applications. We partner with customers to deliver a range of ground-breaking products from cleaned and coated glass substrates through to full microfluidic device development and contract manufacture programs.
Our team brings together the worlds leading capabilities in glass and polymer for microfluidic devices, microarrays, lab-on-a-chip substrates and functional coatings. We build upon SCHOTTs 135-year history in technical glass manufacturing with our 18-year track record, delivering thousands of successful projects and millions of products for customers world-wide.
Cleaned and coated substrates for research, diagnostics and many other life science applications
SCHOTT MINIFAB brings you NEXTERION®, the leading brand for cleaned and coated substrates for research, diagnostics and many other life science applications. With over 135 years of experience in technical glass manufacturing and more than 18 years in the production of diagnostic and lifescience consumables, SCHOTT MINIFAB offers an extensive range of standard products and functional coatings for DNA, protein and cell applications. In addition, we also provide products to meet special customer requirements for unique formats, materials, coatings and markings. Due to our high quality standards and volume production methods, we enable our customers to achieve reproducible results to address future diagnostic challenges successfully.
Are you developing a diagnostic microfluidic product? Validating assay maturity is critical for commercial success.
Assay maturity describes a benchtop assays readiness to be translated to microfluidic cartridge format. It is important for assay developers and microfluidic product developers to properly assess this level of maturity prior to launching a product development program. Although almost every new diagnostic product begins with an assay which functions reliably on a benchtop, this alone is not enough to optimally reduce program risks. Setting a new product up for commercial success requires a thorough investigation and understanding of gaps in data along with identification and mitigation of any critical assumptions. That is why SCHOTT MINIFABs unique approach to assay translation always starts with a thorough assessment and characterisation of the standard benchtop workflow (benchmark assay). It is this deep insight that drives and supports the subsequent stages of the program and underpins the products success.
TearLab® Corporation, together with SCHOTT MINIFAB are celebrating an important milestone with the delivery of the 20 millionth microfluidic eye test card from the production line in Melbourne, Australia. The milestone comes as a result of a 13-year contract manufacturing partnership between the two companies, beginning in 2007 with an ambitious microfluidic product development program.
We partner with clients to deliver game-changing diagnostics and life-science products that drive new discoveries, improve lives, and make the world a healthier place. The products we bring to life are revolutionising healthcare delivery, powering new discoveries, and changing the world.
The devices may be small, but their impacts are huge.